Characteristics | Control | CC | OR (95% CI) | p | RC | OR (95% CI) | p |
---|---|---|---|---|---|---|---|
N | 400 | 264 | 186 | ||||
Age (mean±SD) | 60.89 ± 11.72 | 61.85 ± 12.85 | 1.01 (0.99 - 1.02) | 0.320 | 62.33 ± 11.46 | 1.01 (1.00 - 1.03) | 0.165 |
Gender (male), n (%) | 170 (42.5) | 124 (47.0) | 1.20 (0.88 - 1.64) | 0.257 | 88 (47.3) | 1.21 (0.86 - 1.72) | 0.275 |
Metabolic syndrome, n (%) | 95 (23.8) | 98 (37.1) | 1.90 (1.35 - 2.66) | <.001 | 73 (39.2) | 2.07 (1.43 - 3.01) | <.001 |
Anti-HTN drug or BP ≥ 130/85 mmHg, n (%) | 157 (39.3) | 159 (60.2) | 2.34 (1.71 - 3.22) | <.001 | 120 (64.5) | 2.81 (1.96 - 4.04) | <.001 |
Anti-DM drug or FBS ≥ 100 mg/dl, n (%) | 166 (41.5) | 149 (56.4) | 1.83 (1.33 - 2.50) | <.001 | 104 (55.9) | 1.79 (1.26 - 2.54) | 0.001 |
TG ≥ 150 mg/dl, n (%) | 135 (33.8) | 67 (25.4) | 0.67 (0.47 - 0.94) | 0.022 | 46 (24.7) | 0.65 (0.44 - 0.95) | 0.029 |
BMI ≥ 25 kg/m2, n (%) | 93 (23.3) | 65 (24.6) | 1.08 (0.75 - 1.55) | 0.685 | 51 (27.4) | 1.25 (0.84 - 1.85) | 0.276 |
HDL-C < 40(male)/50(female) mg/dl, n (%) | 78 (19.5) | 113 (42.8) | 3.09 (2.18 - 4.37) | <.001 | 84 (45.2) | 3.40 (2.32 - 4.97) | <.001 |
Tumor size | |||||||
<5 cm | - | 94 (35.6) | - | - | 87 (46.8) | - | - |
≥5 cm | - | 170 (64.4) | - | - | 99 (53.2) | - | - |
TNM stage, n (%) | |||||||
I | - | 22 (8.3) | - | - | 20 (10.8) | - | - |
II | - | 118 (44.7) | - | - | 71 (38.2) | - | - |
III | - | 94 (35.6) | - | - | 79 (42.5) | - | - |
IV | - | 30 (11.4) | - | - | 16 (8.6) | - | - |